natgillin/translations-raw huggingface dataset:
Indgivelsesvej Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Emballage Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium) Blister (PVC/ PVDC/ Aluminium)
blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ aluminium) blister (PVC/ PVDC/ aluminium) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu) blister (PVC/ PVDC/ alu)
Paknings- størrelse 28 56 98 28 56 98 14 14 56 x 1 56 x 1 14 28 56 56 x 1 98 14 28 56 84 84 14 28 56 84 98 56 x 1 30 30 30 90 90 90
28 56 98 28 56 98 14 14 56 x 1 56 x 1 14 28 56 56 x 1 98 14 28 56 56 x 1 98 84 84 14 28 56 84 98 56 x 1 30 30 30 90 90 90
CoAprovel 150 mg/ 12, 5 mg tabletter
CoAprovel 150 mg/ 12.5 mg tablets.
Hver tablet indeholder 150 mg irbesartan og 12, 5 mg hydrochlorthiazid.
Each tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
Hver tablet indeholder 26, 65 mg lactose (som lactosemonohydrat).
Each tablet contains 26.65 mg of lactose (as lactose monohydrate).
5. 1).
This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).
Dosistitrering af de enkelte komponenter (dvs. irbesartan og hydrochlorthiazid) kan anbefales.
Dose titration with the individual components (i. e. irbesartan and hydrochlorothiazide) may be recommended.
CoAprovel 150 mg/ 12, 5 mg kan gives til patienter, hvis blodtryk ikke kan reguleres tilstrækkeligt med hydrochlorthiazid eller irbesartan 150 mg alene; CoAprovel 300 mg/ 12, 5 mg kan gives til patienter, der er utilstrækkeligt regulerede med irbesartan 300 mg eller med CoAprovel 150 mg/ 12, 5 mg.
CoAprovel 150 mg/ 12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone; CoAprovel 300 mg/ 12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by CoAprovel 150 mg/ 12.5 mg.
CoAprovel 300 mg/ 25 mg kan gives til patienter, der er utilstrækkeligt regulerede med CoAprovel 300 mg/ 12, 5 mg.
CoAprovel 300 mg/ 25 mg may be administered in patients insufficiently controlled by CoAprovel 300 mg/ 12.5 mg.
Højere doser end 300 mg irbesartan/ 25 mg hydrochlorthiazid, 1 gang dagligt, frarådes.
Doses higher than 300 mg irbesartan/ 25 mg hydrochlorothiazide once daily are not recommended.
4. 5).
When necessary, CoAprovel may be administered with another antihypertensive medicinal product (see section 4.5).
På grund af hydrochlorthiazid- komponenten anbefales CoAprovel ikke til patienter med alvorlig nyreinsufficiens (kreatininclearance < 30 ml/ min).
Renal impairment: due to the hydrochlorothiazide component, CoAprovel is not recommended for patients with severe renal dysfunction (creatinine clearance < 30 ml/ min).
Loop- diuretika er at foretrække frem for thiazider til denne patientgruppe.
Loop diuretics are preferred to thiazides in this population.
4. 3 og 4. 4).
No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is ≥ 30 ml/ min (see sections 4.3 and 4.4).
Leverfunktionsnedsættelse:
Hepatic impairment:
4. 3).
No dosage adjustment of CoAprovel is necessary in patients with mild to moderate hepatic impairment (see section 4.3).
Dosisjustering af CoAprovel til ældre patienter er ikke nødvendig.
2 Elderly patients: no dosage adjustment of CoAprovel is necessary in elderly patients.
Børn:
Paediatric patients:
CoAprovel frarådes til behandling af børn og unge pga. manglende viden om sikkerhed og virkning.
CoAprovel is not recommended for use in children and adolescents due to a lack of data on safety and efficacy.
Alvorlig nyrefunktionsnedsættelse (kreatininclearance < 30 ml/ min), Refraktær hypokaliæmi, hypercalcæmi, Alvorlig leverfunktionsnedsættelse, biliær cirrhose og cholestase.
Hypersensitivity to the active substances, to any of the excipients (see section 6.1), or to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance) Second and third trimester of pregnancy (see sections 4.4 and 4.6) Lactation (see section 4.6) Severe renal impairment (creatinine clearance < 30 ml/ min) Refractory hypokalaemia, hypercalcaemia Severe hepatic impairment, biliary cirrhosis and cholestasis
CoAprovel er kun sjældent blevet associeret med symptomatisk hypotension hos hypertensive patienter uden andre risikofaktorer for hypotension.
CoAprovel has been rarely associated with symptomatic hypotension in hypertensive patients without other risk factors for hypotension.
Symptomatisk hypotension kan forventes at optræde hos patienter med hypovolæmi og/ eller hyponatriæmi forårsaget af kraftig diuretisk behandling, nedsat saltindtag gennem kosten, diarré eller opkastning.
Symptomatic hypotension may be expected to occur in patients who are volume and/ or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting.
Der er øget risiko for alvorlig hypotension og nyreinsufficiens, hvis patienter med bilateral nyrearteriestenose, eller stenose af arterien til den eneste fungerende nyre, behandles med angiotensin- konverterende enzymhæmmere eller angiotensin- II receptor- antagonister.
Renal artery stenosis - Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists.
Når CoAprovel anvendes til patienter med nedsat nyrefunktion, anbefales periodisk monitorering af serum- kalium, serum- kreatinin og serum- urinsyre - niveauer.
Renal impairment and kidney transplantation: when CoAprovel is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
Der kan forekomme thiaziddiuretika- associeret azotæmi hos patienter med nedsat nyrefunktion.
Thiazide diuretic-associated azotemia may occur in patients with impaired renal function.
Det er ikke nødvendigt at justere dosis hos patienter med nedsat nyrefunktion, hvis kreatininclearance er ≥ 30 ml/ min.
No dosage adjustment is necessary in patients with renal impairment whose creatinine clearance is ≥ 30 ml/ min.
Dog skal denne faste dosis- kombination gives med forsigtighed til patienter med mild til moderat nedsat nyrefunktion (kreatininclearance ≥ 30 ml/ min, men < 60 ml/ min).
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/ min but < 60 ml/ min) this fixed dose combination should be administered with caution.
Thiazider skal anvendes med forsigtighed til patienter med nedsat leverfunktion eller progressiv leversygdom, da mindre ændringer af væske - og elektrolytbalancen kan fremskynde hepatisk koma.
Hepatic impairment: thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
Som ved behandling med andre vasodilatorer skal der udvises ekstra forsigtighed hos patienter, der lider af aorta - eller mitralstenose eller obstruktiv hypertrofisk kardiomyopati.
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
Patienter med primær aldosteronisme responderer generelt ikke på antihypertensive stoffer, der virker gennem hæmning af renin- angiotensinsystemet.
Primary aldosteronism: patients with primary aldosteronism generally will not respond to anti- hypertensive medicinal products acting through inhibition of the renin-angiotensin system.
Thiazidbehandling kan svække glukosetolerancen.
Metabolic and endocrine effects: thiazide therapy may impair glucose tolerance.
Der er dog rapporteret minimal eller ingen effekt ved en dosis på 12, 5 mg, som findes i CoAprovel.
Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however at the 12.5 mg dose contained in CoAprovel, minimal or no effects were reported.
3 Der kan forekomme hyperurikæmi, eller regulær urinsyregigt kan blive fremskyndet, hos visse patienter i thiazidbehandling.
3 Hyperuricaemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy.
Som for alle patienter i diuretisk behandling, skal der med passende mellemrum foretages periodisk kontrol af serum- elektrolytter.
Electrolyte imbalance: as for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.
Thiazider, inklusive hydrochlorthiazid, kan medføre væske - eller elektrolytforstyrrelser (hypokaliæmi, hyponatriæmi og hypokloræmisk alkalose).
Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypokalaemia, hyponatraemia, and hypochloremic alkalosis).
Advarselstegn på væske - eller elektrolytforstyrrelser kan være mundtørhed, tørst, svækkelse, sløvhed, døsighed, rastløshed, muskelsmerter eller kramper, muskulær træthed, hypotension, oliguri, takykardi og gastrointestinale forstyrrelser, såsom kvalme og opkastning.
Warning signs of fluid or electrolyte imbalance are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting.
Selvom thiaziddiuretika kan udvikle hypokaliæmi, kan samtidig behandling med irbesartan reducere diuretika- induceret hypokaliæmi.
Although hypokalaemia may develop with the use of thiazide diuretics, concurrent therapy with irbesartan may reduce diuretic-induced hypokalaemia.
Det er især tilfældet ved nyrefunktionsnedsættelse og/ eller hjertesygdom og diabetes mellitus.
Conversely, due to the irbesartan component of CoAprovel hyperkalaemia might occur, especially in the presence of renal impairment and/ or heart failure, and diabetes mellitus.
Adækvat monitorering af serum - kalium anbefales hos patienter i risikogruppen.
Adequate monitoring of serum potassium in patients at risk is recommended.
4. 5).
Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with CoAprovel (see section 4.5).
Der er ingen tegn på, at irbesartan reducerer eller forebygger diuretika- induceret hyponatriæmi.
There is no evidence that irbesartan would reduce or prevent diuretic-induced hyponatraemia.
Thiazider kan sænke urin- calciumudskillelsen og forårsage intermitterende og let forhøjelse af serum - calcium uden kendte forstyrrelser af calciummetabolismen.
Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism.
4. 5).
Lithium: the combination of lithium and CoAprovel is not recommended (see section 4.5).
Indholdet af hydrochlorthiazid i dette lægemiddel kan medføre et positivt fund ved en doping- test.
Anti-doping test: hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an anti-doping test.
Hos patienter, hvis vaskulære tonus og nyrefunktion hovedsageligt afhænger af renin - angiotensin- aldosteronsystemets aktivitet (fx patienter med alvorlig hjerteinsufficiens eller underliggende nyresygdom, inklusive nyrearteriestenose), er behandling med angiotensin - konverterende enzymhæmmere eller angiotensin- II receptorantagonister, der påvirker dette system, blevet forbundet med akut hypotension, azotæmi, oliguri og i sjældne tilfælde akut nyresvigt.
General: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e. g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotemia, oliguria, or rarely acute renal failure.
Sandsynligheden er dog større hos patienter med allergisk eller bronkial astma- anamnese.
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.
4. 8).
Cases of photosensitivity reactions have been reported with thiazides diuretics (see section 4.8).
Hvis det er nødvendigt at genoptage diuretika- behandlingen, anbefales det at beskytte udsatte områder mod sol og kunstige UVA- stråler.
If a re- administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.
Patienter, der planlægger at blive gravide, bør ændre til anden antihypertensiv behandling hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, medmindre fortsat behandling med AIIRA skønnes nødvendig.
Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
Dette lægemiddel indeholder lactose.
4 Lactose: this medicinal product contains lactose.
Patienter med sjældne arvelige problemer med galactoseintolerans, Lapp- lactase eller glucose- galactosemalabsorption bør ikke anvende dette lægemiddel.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
CoAprovels antihypertensive virkning kan øges ved samtidig administration af andre antihypertensive stoffer.
Other antihypertensive agents: the antihypertensive effect of CoAprovel may be increased with the concomitant use of other antihypertensive agents.
Irbesartan og hydrochlorthiazid (i doser på op til 300 mg irbesartan/ 25 mg hydrochlorthiazid) er administreret samtidig med andre antihypertensive stoffer, inklusive calcium- blokkere og beta- adrenerge blokkere, uden problemer.
Irbesartan and hydrochlorothiazide (at doses up to 300 mg irbesartan/ 25 mg hydrochlorothiazide) have been safely administered with other antihypertensive agents including calcium channel blockers and beta-adrenergic blockers.
Der er blevet rapporteret reversibel øgning af serum- lithiumkoncentrationer og toksicitet ved samtidig administration af lithium og angiotensin- konverterende enzymhæmmere.
Lithium: reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors.
4. 4).
Therefore, the combination of lithium and CoAprovel is not recommended (see section 4.4).
Den kalium- depleterende virkning af hydrochlorthiazid dæmpes af irbesartans kalium- besparende effekt.
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of irbesartan.
En sådan indvirkning af hydrochlorthiazid på serum- kalium kan dog forventes at blive forstærket af andre stoffer associeret med kaliumtab og hypokaliæmi (fx andre kalium- diuretika, laxantia, amphotericin, carbenoxolon, penicillin G natrium).
However, this effect of hydrochlorothiazide on serum potassium would be expected to be potentiated by other medicinal products associated with potassium loss and hypokalaemia (e. g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium).
Baseret på erfaringer med andre præparater, som dæmper renin- angiotensinsystemet, har det omvendt vist sig, at samtidig brug af kaliumbesparende diuretika, kaliumtilskud, kaliumholdige salterstatninger eller andre præparater, der kan øge serum- kalium, fx heparinnatrium, kan øge serum- kalium.
Conversely, based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e. g. heparin sodium) may lead to increases in serum potassium.
4. 4).
Adequate monitoring of serum potassium in patients at risk is recommended (see section 4.4).
Det anbefales at måle serum- kalium periodisk, når CoAprovel administreres sammen med lægemidler, der påvirkes af serum- kaliumforstyrrelser (fx digitalisglykosider, antiarytmika).
Medicinal products affected by serum potassium disturbances: periodic monitoring of serum potassium is recommended when CoAprovel is administered with medicinal products affected by serum potassium disturbances (e. g. digitalis glycosides, antiarrhythmics).
Når angiotensin II- antagonister administreres samtidig med nonsteroide antiinflammatoriske lægemidler (fx selektive COX- 2- hæmmere, acetylsalicylsyre (> 3 g/ dag) og non- selektive NSAID) kan den antihypertensive virkning svækkes.
Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously with non-steroidal anti- inflammatory drugs (i. e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/ day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Det gælder især hos patienter, som i forvejen har dårlig nyrefunktion.
As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.
Irbesartans farmakokinetik er i kliniske forsøg ikke blevet påvirket af hydrochlorthiazid.
Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
Effekten af CYP2C9- induktorer, som fx rifampicin på irbesartans farmakokinetik er ikke evalueret.
The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated.
Ved samtidig administration kan følgende stoffer give anledning til interaktioner med thiaziddiuretika:
Additional information on hydrochlorothiazide interactions: when administered concurrently, the following medicinal products may interact with thiazide diuretics:
Der kan forekomme forstærket ortostatisk hypotension;
5 Alcohol: potentiation of orthostatic hypotension may occur;
4. 4);
Antidiabetic medicinal products (oral agents and insulins): dosage adjustment of the antidiabetic medicinal product may be required (see section 4.4);
Absorption af hydrochlorthiazid nedsættes ved tilstedeværelse af anione resiner;
Colestyramine and Colestipol resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins;
Elektrolytdepletion, specielt hypokaliæmi, kan forstærkes;
Corticosteroids, ACTH: electrolyte depletion, particularly hypokalaemia, may be increased;
4. 4);
Digitalis glycosides: thiazide induced hypokalaemia or hypomagnaesemia favour the onset of digitalis-induced cardiac arrhythmias (see section 4.4);
Administration af et non- steroidt antiinflammatorisk lægemiddel kan reducere den diuretiske, natriuretiske og antihypertensive virkning af thiaziddiuretika hos nogle patienter;
Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;
Virkningen af aminer, der sænker blodtrykket kan nedsættes, men ikke tilstrækkeligt til at udelukke deres anvendelse;
Pressor amines (e. g. noradrenaline): the effect of pressor amines may be decreased, but not sufficiently to preclude their use;
Virkningen af nondepolariserende skelet/ muskel- relaxanter kan forstærkes af hydrochlorthiazid;
Nondepolarizing skeletal muscle relaxants (e. g. tubocurarine): the effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide;
Det kan være nødvendigt at justere dosis af lægemidlet mod urinsyregigt, da hydrochlorthiazid kan øge niveauet af urinsyre i serum.
Antigout medicinal products: dosage adjustments of antigout medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid.
Thiaziddiuretika kan øge serum- calciumniveauet på grund af nedsat udskillelse.
Calcium salts: thiazide diuretics may increase serum calcium levels due to decreased excretion.
Hvis der gives calciumsupplement eller calciumbesparende lægemiddel (fx D- vitamin), skal serum- calcium niveauet måles, og calcium- dosis justeres herefter;
If calcium supplements or calcium sparing medicinal products (e. g. vitamin D therapy) must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly;
Den hyperglykæmiske effekt af beta- blokkere og diazoxid kan forstærkes af thiazider.
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.
Antikolinerge stoffer (fx atropin, beperiden) kan øge biotilgængeligheden af thiaziddiuretika ved at nedsætte den gastrointestinale bevægelighed og ventrikeltømningshastigheden.
Anticholinergic agents (e. g. atropine, beperiden) may increase the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.
Thiazider kan reducere nyreudskillelsen af cytotoksiske stoffer (fx cyklofosfamid, methotrexat) og forstærke deres myelosuppresive effekt.
Thiazides may reduce the renal excretion of cytotoxic medicinal products (e. g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.
4. 4).
Pregnancy: the use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4).